Six-month clinical status as a predictor of 24-month clinical outcome in first-admission patients with schizophrenia

Annals of Clinical Psychiatry

Volumn 11, Issue 4, 1999, Pages 197-203

  Craig, Thomas ^a   Fennig, Shmuel ^b   Tanenberg Karant, Marsha ^c   Bromet, Evelyn J ^c  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b Shelvata Hospital   (Israel)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

First admission; Negative symptoms; Outcome; Psychotic symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ALCOHOL ABUSE; ARTICLE; CONTROLLED STUDY; DELUSION; FEMALE; FOLLOW UP; HALLUCINATION; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PREDICTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 0032706829     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.3109/10401239909147071     Document Type: Article

References (41)

1. Kane J, Honigfeld G, Singer J, Meltzer H: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
2. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151 (6 suppl.):825-835
3. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM: Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994; 151:1774-1752
4. Carpenter WT Jr, Conley RR, Buchanan RW, Breier A, Tamminga CA: Patient response and resource management: another view of clozapine treatment of schizophrenia. Am J Psychiatry 1995; 152:827-832
5. Ereshefsky L: Treatment strategies for schizophrenia. Psychiatr Ann 1995; 25:285-296
6. Wasylenki DA: Psychotherapy of schizophrenia revisited. Hosp Commun Psychiatry 1992; 43:123-127
7. Burns BJ, Santos AB: Assertive community treatment: an update of randomized trials. Psychiatr Serv 1995; 46:669-675
8. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630-1638
9. Ghaemi SN, Ziegler DM, Peachey TJ, Goodwin FK: Cost-effectiveness of clozapine therapy for severe psychosis. Psychiatr Serv 1998; 49:829-831
10. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D: A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia [see comments]. N Engl J Med 1997; 337:809-815
11. Albright PS, Livingstone S, Keegan DL, Ingham M, Shrikhande S, LeLorier J: Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy - a retrospective analysis using the Saskatchewan Health Linkable Databases. Clin Drug Invest 1996; 11:289-299
12. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 197; 154:1248-1254
13. Davies A, Langley PC, Keks NA, Catts SV, Lambert T, Schweitzer I: Risperidone versus haloperidol: II. cost-effectiveness. Clin Ther 1998; 20:196-213
14. Marder SR, Van Putten T: Who should receive clozapine? Arch Gen Psychiatry 1988 45:865-867
15. Hoge MA, Davidson L, Griffith EE, Sledge WH, Howenstine RA: Defining managed care in public sector psychiatry. Hosp Commun Psychiatry 1994; 45:1085-1089
16. Garnick DW, Hendricks AM, Dulski JD, Thorpe KE, Horgan C: Characteristics of private-sector managed care for mental health and substance abuse treatment. Hosp Commun Psychiatry 1994; 45:1201-1205
17. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr: Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151:20-26
18. Bromet EJ, Jandorf L, Fennig S, Lavelle J, Kovasznay B, Ram R, Tanenberg-Karant M, Craig T: Premorbid and clinical predictors of short-term course in first-admission psychotic patients: Preliminary results. Psychol Med 1996; 26:953-962
19. Spitzer RL, Williams J, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID) I: history, rationale and description. Arch Gen Psychiatry 1992; 49:624-629
20. Fennig S, Kovasznay B, Rich C, Ram R, Pato C, Miller A, Rubinstein J, Carlson G, Schwartz JE, Phelan J, Lavelle J, Craig T, Bromet E: Six-month stability of psychiatric diagnosis in first admission patients with psychosis. Am J Psychiatry 1994; 151:1200-1208
21. Andreasen NC, Arndt S, Alliger R, Miller D, Flaum M: Symptoms of schizophrenia: methods, meanings, and mechanisms. Arch Gen Psychiatry 1995; 52:341-351
22. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, Day R, Bertelsen A: Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med 1992(monograph suppl 1992); 20:1-97
23. Woerner MG, Mannuzza S, Kane JM: Anchoring the BPRS: an aid to improved reliability. Psychopharm Bull 1988; 24:112-117
24. Heinrichs DW, Hanlon TE, Carpenter WT Jr: The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10:388-398
25. Marengo J, Harrow M, Sands J, Galloway C: European versus United States data on the course of schizophrenia. Am J Psychiatry 1991; 148:606-611
26. Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994; 151:1409-1416
27. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE: The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 1992; 18:185-201
28. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharm 1993; 13:25-40
29. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
30. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995; 166:712-26
31. Keefe RSE, Mohs RC, Losonczy MF, Davidson M, Silverman JM, Kendler KS, Horvath TB, Nora R, Davis KL: Characteristics of very poor outcome schizophrenia. Am J Psychiatry 1987; 144:889-895
32. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, Cooper TB, Brodie JD: Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989; 146:905-908
33. Peralta V, de Leon J, Cuesta MJ: Are there more than two syndromes in schizophrenia? a critique of the positive-negative dichotomy. Br J Psychiatry 1992; 161:335-343
34. Yates WR, Jacoby CG, Andreasen NC: Cerebellar atrophy in schizophrenia and affective disorder. Am J Psychiatry 1987; 144:465-467
35. Smith JV, Birchwood MJ: Specific and non-specific effects of educational intervention with families living with a schizophrenic relative. Br J Psychiatry 1987; 150:645-652
36. Liddle PF: Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 1987; 17:49-57
37. Breier A, Schreiber JL, Dyer J, Pickar D: The National Institute of Mental Health longitudinal study of chronic schizophrenia. Arch Gen Psychiatry 1991; 48:239-246
38. Harrow M, Grinker RR, Silverstein ML, Holzman P: Is modern-day schizophrenia outcome still negative? Am J Psychiatry 1978; 135:1156-1162
39. Lieberman J, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry 1993; 50:369-376
40. Schooler NR: Translating treatment research findings into clinical action [editorial]. Am J Psychiatry 1994; 151:1719-1721
41. Harding CM, Zubin J, Strauss JS: Chronicity in schizophrenia: fact, partial fact, or artifact? Hosp Commun Psychiatry 1987; 38:477-486